Source link : https://www.newshealth.biz/health-news/car-t-not-a-clear-winner/
NEW YORK — In a three-way debate on whether to prioritize chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies (BsAbs), or one of the novel oral targeted therapies for relapsed/refractory follicular lymphoma (R/R FL), no expert conceded. Acknowledging that hers was the weakest position, even the specialist who defended novel targeted therapies mounted a staunch […]
Author : News Health
Publish date : 2024-10-24 14:12:14
Copyright for syndicated content belongs to the linked Source.